GTP Cyclohydrolase 1 Deficiency Overview

Save information for later
Sign Up

Learn About GTP Cyclohydrolase 1 Deficiency

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top GTP Cyclohydrolase 1 Deficiency Local Doctors?
Elite in GTP Cyclohydrolase 1 Deficiency
Elite in GTP Cyclohydrolase 1 Deficiency
Oxford, ENG, GB 

Surawee Chuaiphichai practices in Oxford, United Kingdom. Chuaiphichai is rated as an Elite expert by MediFind in the treatment of GTP Cyclohydrolase 1 Deficiency. Their top areas of expertise are GTP Cyclohydrolase 1 Deficiency, Phenylketonuria (PKU), Vasoconstriction, and Familial Glucocorticoid Deficiency.

Elite in GTP Cyclohydrolase 1 Deficiency
Elite in GTP Cyclohydrolase 1 Deficiency
Oxford, ENG, GB 

Eileen Mcneill practices in Oxford, United Kingdom. Ms. Mcneill is rated as an Elite expert by MediFind in the treatment of GTP Cyclohydrolase 1 Deficiency. Her top areas of expertise are GTP Cyclohydrolase 1 Deficiency, Phenylketonuria (PKU), Atherosclerosis, and Thoracic Aortic Aneurysm.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in GTP Cyclohydrolase 1 Deficiency
Elite in GTP Cyclohydrolase 1 Deficiency
Roosevelt Drive, 
Oxford, ENG, GB 

Gillian Douglas practices in Oxford, United Kingdom. Ms. Douglas is rated as an Elite expert by MediFind in the treatment of GTP Cyclohydrolase 1 Deficiency. Her top areas of expertise are GTP Cyclohydrolase 1 Deficiency, Atherosclerosis, Thoracic Aortic Aneurysm, Phenylketonuria (PKU), and Stent Placement.

What are the latest GTP Cyclohydrolase 1 Deficiency Clinical Trials?
A Phase Ib/II Open-Label Study of APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma and Immunoglobin Light Chain Amyloidosis

Summary: This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy, and PK/ Pharmacodynamics of APG-2575 in combination with Pd/DRd in patients with relapsed/refractory (RR) multiple myeloma (MM). The study consists of dose escalation and dose expansion phases. The study consists of will start with 2 arms noted below, both arms are independent

Match to trials
Find the right clinical trials for you in under a minute
Get started